Naples, FL – According to filings with the U.S. Securities and Exchange Commission, Enveric Biosciences is raising $8,249,959.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, John VanBuiten played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments. Enveric Biosciences has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. As a focused support care company, Enveric Biosciences leverages innovative clinical developments derived from cannabinoids and taps into its global network of scientists and oncology physicians.

To learn more about Enveric Biosciences, visit http://www.enveric.com/

Contact:
John VanBuiten, Chief Financial Officer
239-302-1707
https://www.linkedin.com/in/johnvanbuiten/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved